Generic Medicine Info
Indications and Dosage
Ankylosing spondylitis, Osteoarthritis, Rheumatoid arthritis
Adult: As conventional tab or soft gel cap: 100 mg bid, in the morning and the evening. As sustained-release tab: 200 mg once daily.
Elderly: As conventional tab or soft gel cap: Use the lowest effective dose for the shortest possible duration.
Renal Impairment
Mild to moderate: As conventional tab or soft gel cap: Use the lowest effective dose for the shortest possible duration. Severe: Contraindicated.
Hepatic Impairment
Mild to moderate: As conventional tab or soft gel cap: Initially, 100 mg daily. Severe: Contraindicated.
Should be taken with food. Take w/ or immediately after meals.
Hypersensitivity to aceclofenac, aspirin, ibuprofen or other NSAIDs. Active or history of peptic ulcer/haemorrhage, active bleeding or bleeding disorders, history of gastrointestinal bleeding or perforation related to previous NSAID therapy; CHF (NYHA class II-IV), ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, severe heart failure, varicella infection. Severe hepatic and renal impairment. Pregnancy (3rd trimester).
Special Precautions
Patient with history of bronchial asthma, history of gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease); fluid retention, hypertension, mild to moderate CHF or CHF NYHA class I, history of MI, stroke, or cerebrovascular bleeding; coagulation disorders, anaemia, SLE, hepatic porphyria. Patient undergoing or after CABG. Mild to moderate hepatic and renal impairment. Elderly. Pregnancy (1st-2nd trimester) and lactation.
Adverse Reactions
Significant: CV thrombotic events, including MI and stroke; fluid retention and oedema, new-onset or exacerbation of hypertension, haematologic effects (e.g. decreased platelet adhesion and aggregation, prolonged bleeding time), hyperkalaemia, increased transaminases, renal effects (e.g. deteriorated renal function, precipitated renal failure), drowsiness, dizziness, blurred vision, photosensitivity; hypersensitivity reactions, including anaphylactic or anaphylactoid reactions. Rarely, blood dyscrasias (e.g. aplastic anaemia, thrombocytopenia, agranulocytosis), hepatitis, aseptic meningitis (particularly in patients with SLE and mixed connective tissue disorders).
Gastrointestinal disorders: Nausea, diarrhoea, dyspepsia, abdominal pain, vomiting, constipation, flatulence, gastritis, mouth ulceration.
Investigations: Increased blood BUN and creatinine.
Skin and subcutaneous tissue disorders: Rash, pruritus, dermatitis, urticaria.
Potentially Fatal: Gastrointestinal bleeding, ulceration and perforation, severe bronchospasm. Rarely, serious skin reactions (e.g. Stevens-Johnsons syndrome, toxic epidermal necrolysis, exfoliative dermatitis).
Patient Counseling Information
This drug may cause drowsiness, dizziness or blurred vision, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor LFTs periodically, renal function tests (urine output, serum BUN, creatinine), blood pressure, CBC, serum K, and occult blood loss. Perform ophthalmic exam as necessary (long-term use).
Symptoms: Headache, vomiting, nausea, epigastric pain, gastrointestinal irritation and bleeding, diarrhoea, disorientation, excitation, dizziness, drowsiness, tinnitus, hypotension, fainting, convulsions, respiratory depression, coma, and renal failure or liver damage for significant doses. Management: Symptomatic and supportive treatment. Give activated charcoal or perform gastric lavage within 1 hour of ingestion. Administer IV diazepam for frequent or prolonged convulsions. Closely monitor renal and hepatic function.
Drug Interactions
Increased risk of gastrointestinal ulceration and bleeding with anticoagulants (e.g. warfarin), corticosteroids, and SSRIs. Increased risk of nephrotoxicity with diuretics, ciclosporin, and tacrolimus. May inhibit the renal clearance resulting in increased plasma levels of cardiac glycosides (e.g. digoxin) and lithium. May enhance the risk of renal insufficiency with ACE inhibitors or angiotensin II receptor antagonists. May increase the plasma levels and toxicity of methotrexate. May decrease the effects of mifepristone. May enhance the risk of convulsions with quinolones.
Potentially Fatal: Increased risk of gastrointestinal ulceration and bleeding with other NSAIDs, COX-2 selective inhibitors, and antiplatelets (e.g. aspirin).
Food Interaction
Increased risk of gastrointestinal bleeding with alcohol.
Lab Interference
May result in a false-positive aldosterone/renin ratio (ARR).
Mechanism of Action: Aceclofenac, a phenylacetic acid derivative, a potent inhibitor of cyclooxygenase (COX) enzyme which is involved in the production of prostaglandins, thereby causing marked anti-inflammatory and analgesic effects.
Absorption: Rapidly and completely absorbed from the gastrointestinal tract (conventional tab). Time to peak plasma concentration: 1-3 hours (conventional tab).
Distribution: Penetrates the synovial fluid. Volume of distribution: Approx 25 L (conventional tab). Plasma protein binding: >99% (conventional tab).
Metabolism: Metabolised into 4'-hydroxyaceclofenac.
Excretion: Via urine (approx 2/3 mainly as hydroxymetabolites). Elimination half-life: Approx 4 hours (conventional tab).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 71771, Aceclofenac. Accessed Apr. 26, 2021.

Store below 30°C.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AB16 - aceclofenac ; Belongs to the class of acetic acid derivatives and related substances of non-steroidal antiinflammatory and antirheumatic products.
Airtal 100 mg Film-Coated Tablet (Zuellig Pharma Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 05/03/2021.

Anon. Aceclofenac. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/03/2021.

Buckingham R (ed). Aceclofenac. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/03/2021.

Clanza/Clanza CR/Clanza S (One Pharma Co, Inc). MIMS Philippines. Accessed 05/03/2021.

Dolowin SR (Brown & Burk Phils., Inc.). MIMS Philippines. Accessed 05/03/2021.

Joint Formulary Committee. Aceclofenac. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 05/03/2021.

Preservex 100 mg Film-Coated Tablets (Almirall, S.A.). MHRA. Accessed 05/03/2021.

Disclaimer: This information is independently developed by MIMS based on Aceclofenac from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in